论文部分内容阅读
目的探讨T2DM患者血浆网膜素水平的变化及利拉鲁肽治疗对网膜素水平的影响。方法采用酶联免疫法测定T2DM患者及正常人血浆网膜素水平,分析血浆网膜素水平与BMI、WHR、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞分泌指数(HOMA-IS)、FFA等的关系,观察利拉鲁肽治疗前后T2DM患者血浆网膜素水平的变化。结果 T2DM患者血浆网膜素水平明显低于正常人[(19.3±3.9)vs(26.4±6.0)μg/L,P<0.01]。T2DM患者血浆网膜素水平与FIns、HOMA-IR呈负相关(r=-0.41,P<0.05和r=-0.56,P<0.01)。T2DM患者经利拉鲁肽治疗后WHR、BMI、FPG、2hPG和HbA1c均显著降低(P均<0.01),而HOMA-IS则显著增高(P<0.01),空腹血浆网膜素水平也显著增高[(19.3±3.9)vs(21.2±3.8)μg/L,P<0.01]。结论利拉鲁肽能有效改善T2DM患者糖代谢和IS,同时升高血浆网膜素水平。
Objective To investigate the changes of plasma retinin in patients with T2DM and the effects of liraglutide on the level of retinal. Methods The plasma levels of retinin in T2DM patients and normal subjects were measured by enzyme-linked immunosorbent assay (ELISA). Plasma levels of retinulin were compared with those of BMI, WHR, HOMA-IR, HOMA-IS, Etc, to observe the changes of plasma retinin in patients with T2DM before and after treatment with liraglutide. Results Plasma retinin levels in T2DM patients were significantly lower than those in normal controls [(19.3 ± 3.9) vs (26.4 ± 6.0) μg / L, P <0.01]. Plasma retinin levels were negatively correlated with FIns and HOMA-IR in T2DM patients (r = -0.41, P <0.05 and r = -0.56, P <0.01). The WHR, BMI, FPG, 2hPG and HbA1c in T2DM patients after treatment with liraglutide were significantly lower (all P <0.01), while those in HOMA-IS were significantly higher (P <0.01) [(19.3 ± 3.9) vs (21.2 ± 3.8) μg / L, P <0.01]. Conclusion Liraglutide can effectively improve glycometabolism and IS in T2DM patients and increase plasma retinin levels.